A172 Xenograft Model Service for Glioblastoma

The A172 Xenograft Model Service for Glioblastoma provides a robust, clinically relevant platform for evaluating therapeutic candidates against one of the most aggressive primary brain tumors. Alfa Cytology leverages validated A172 cell line-derived xenograft systems to support preclinical drug development, biomarker discovery, and mechanistic studies in glioblastoma research.

Overview of A172 Xenograft Model for Glioblastoma

Glioblastoma multiforme (GBM) represents the most common and lethal primary brain malignancy, characterized by rapid proliferation, diffuse infiltration, and pronounced therapeutic resistance. Cell line-derived xenograft (CDX) models have become indispensable tools in preclinical neuro-oncology research, offering standardized, reproducible platforms to investigate tumor biology and evaluate therapeutic interventions. Among the established GBM cell lines, A172 has emerged as a widely utilized model system due to its well-defined molecular characteristics and reliable tumorigenicity in immunocompromised hosts.

The A172 cell line was originally isolated from a 53-year-old male patient diagnosed with glioblastoma multiforme. These cells exhibit an epithelial-like morphology in culture and maintain a mesenchymal gene expression profile, expressing markers such as CD90, CD105, fibroblast activation protein (FAP), and tenascin C. A172 cells demonstrate elevated expression of pro-angiogenic factors including vascular endothelial growth factor (VEGF), basic fibroblast growth factor (FGF2), and transforming growth factor-beta 1 (TGF-beta1), recapitulating key features of GBM vascularization. The A172 xenograft model supports both subcutaneous and orthotopic implantation strategies, enabling researchers to assess tumor growth kinetics, drug pharmacokinetics, blood-brain barrier penetration, and systemic toxicity in a controlled preclinical setting.

Figure 1. Curcumin treatment enhanced cell death and autophagy in glioblastoma cells. (Lee, Jong-Eun, et al., 2019)

Cell Line Information: A172

The A172 cell line serves as a well-characterized model for glioblastoma multiforme research. The following table summarizes essential cell line characteristics, growth requirements, and molecular features relevant to xenograft model development.

Our Services

Alfa Cytology provides comprehensive A172 Xenograft Model Services tailored to advance your glioblastoma therapeutic pipeline. Our preclinical oncology team delivers validated subcutaneous and orthotopic A172 xenograft systems with integrated bioluminescence imaging, histopathological analysis, and molecular profiling capabilities. From initial cell line authentication through endpoint analysis, we ensure rigorous quality control, reproducible tumor growth, and clinically relevant data generation to support your IND-enabling studies and publication requirements.

Workflow of A172 Xenograft Model Construction

The construction of A172 xenograft models follows a standardized, multi-step protocol designed to ensure reproducible tumor formation, animal welfare compliance, and high-quality data output. Both subcutaneous (flank) and orthotopic (intracranial) implantation routes are available, with the latter providing superior clinical relevance for blood-brain barrier and CNS penetration studies.

1. Cell Line Authentication & Expansion: A172 cells are authenticated via STR profiling against ATCC/DSMZ databases, confirmed mycoplasma-free, and expanded under standardized culture conditions (DMEM + 10% FBS, 37 degrees C, 5% CO2) to achieve sufficient cell numbers for implantation.
2. Cell Harvesting & Preparation: Confluent cultures are harvested using trypsin-EDTA digestion, washed with PBS, and viability is assessed by trypan blue exclusion (target viability >95%). Cell suspensions are concentrated to the appropriate density (typically 1x10^6 to 5x10^6 cells per 100--200 uL).
3. Matrigel Mixing & Cell Suspension: Harvested A172 cells are resuspended in a 1:1 mixture of serum-free medium and high-concentration Matrigel (or equivalent basement membrane matrix) on ice to preserve matrix integrity and enhance engraftment efficiency.
4. Animal Preparation & Anesthesia: Immunodeficient mice (NOD/SCID, NSG, or BALB/c nude, 5--8 weeks old) are acclimatized for 7 days. Anesthesia is induced using isoflurane inhalation or ketamine/xylazine intraperitoneal injection, with continuous monitoring of respiratory rate and pedal reflex.
5. Tumor Cell Implantation: For subcutaneous models, 1--5x10^6 cells are injected into the flank using a 25--27G needle. For orthotopic models, 3x10^5 cells are stereotactically injected into the right striatum (coordinates: 0.5 mm anterior, 2.0 mm lateral to bregma, 3.0 mm depth) via a burr hole and Hamilton syringe at a rate of 1 uL/min.
6. Post-Operative Monitoring: Animals recover on heated pads with analgesic administration (buprenorphine or carprofen) per IACUC guidelines. Body weight, neurological signs (hunching, circling, lethargy), and wound integrity are monitored daily for the first 7 days.
7. Tumor Growth Monitoring: Subcutaneous tumors are measured twice weekly via digital calipers (volume = 0.5 x length x width^2). Orthotopic tumors are monitored by bioluminescence imaging (BLI) following intraperitoneal luciferin injection (150 mg/kg), with imaging performed weekly under anesthesia.
8. Treatment & Endpoint Analysis: Upon reaching target tumor volume (typically 100--200 mm^3 for SC; 1x10^6--1x10^7 photons/s for orthotopic BLI), animals are randomized into treatment cohorts. Endpoints include tumor growth delay (TGD), tumor growth inhibition (TGI), survival analysis, immunohistochemistry (Ki-67, CD31, TUNEL), qPCR/NGS profiling, and flow cytometry of tumor-infiltrating immune cells.

Figure 2. A172 xenograft model construction workflow.

Case Study-A172 Xenograft Model Development

Alfa Cytology has successfully established and validated A172 xenograft models for multiple client programs targeting glioblastoma therapeutics. Our internal validation studies demonstrate consistent tumor take rates exceeding 90% in both subcutaneous and orthotopic configurations, with predictable growth kinetics suitable for pharmacological intervention studies. Representative data from recent A172 xenograft development projects---including tumor growth curves, survival analyses, and histopathological correlations---are available for review under confidentiality agreements. These datasets illustrate the model's utility in evaluating small molecule inhibitors, antibody-drug conjugates, and combination regimens with temozolomide or radiation therapy. Please contact our scientific team to discuss specific case study data relevant to your therapeutic program and target mechanism.

Why Choose Alfa Cytology?

Alfa Cytology distinguishes itself as a specialized preclinical CRO through rigorous scientific execution, comprehensive model validation, and client-centric study design. Our A172 xenograft service integrates technical excellence with operational flexibility to accelerate your glioblastoma drug development timeline.

• Validated Model Systems: STR-authenticated A172 cell lines with confirmed mycoplasma negativity and documented tumorigenicity in multiple immunodeficient strains.
• Dual Implantation Expertise: Proven capabilities in both subcutaneous (high-throughput screening) and orthotopic (CNS-relevant pharmacology) A172 xenograft configurations.
• Advanced Imaging Integration: In-house bioluminescence imaging (BLI) and MRI capabilities for non-invasive orthotopic tumor monitoring and treatment response assessment.
• Comprehensive Endpoint Portfolio: Histopathology, immunohistochemistry (IHC), immunofluorescence, qPCR, Western blot, flow cytometry, and NGS-based molecular profiling available under one contract.
• Regulatory Compliance: All studies conducted under IACUC-approved protocols with AAALAC-accredited vivarium standards, ensuring data integrity for IND submissions and peer-reviewed publications.
• Flexible Study Design: Customizable treatment schedules, combination therapy arms, and pharmacokinetic/pharmacodynamic (PK/PD) sampling to align with your specific development objectives.
• Dedicated Scientific Support: PhD-level study directors assigned to each project, providing weekly progress updates, interim data reviews, and manuscript-ready reporting formats.

Contact Us

Ready to advance your glioblastoma therapeutic program with a validated A172 xenograft model? Contact us today to discuss your specific study requirements, receive a detailed proposal, and consult with our PhD-level scientific team about the optimal model configuration for your research objectives. Please reach out to us today via our inquiry form or email to learn more about our A172 Xenograft Model services.

For research use only. Not intended for any clinical use.